Based in Martinsried, Germany, MorphoSys (MOR) is a pharmaceutical company committed to antibody development. All antibodies, created by MorphoSys, are composed of 100% protein. The company’s most advanced technology, HuCAL, is designed to approach drug discovery in a smart new way. In total, MorphoSys has developed a portfolio of over 100 human antibodies built with such compounds as guselkumab, anetumab ravtansine, gantenerumab. MorphoSys stock is quoted at Frankfurt Stock Exchange. The company is featured in the TecDAX index. Stay tuned to the MOR stock price info with Capital.com.